# Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

> **NCT03084939** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 351 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Trastuzumab Emtansine
- **DRUG:** Lapatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03084939
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2018-11-23
- **Final completion:** 2023-03-14
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084939, "Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03084939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*